An FDA direct final rule changes inspections from every two years to a risk-based schedule. While this does not clear the convoluted regulatory pathway for biologics, it does represent an attempt to remove inefficient policies that add to costs and reduce access without improving safety.
Early last year,
ORTHOWORLD published results of an industry survey. Among the questions, we asked participants to predict: In 2017, where will the opportunities lie for you and your company? Let's look back at what happened.
Smith & Nephew reports a 97.3% decrease in hospital re-admissions following total joint reconstructions performed under eCap. The program combines Smith & Nephew implants with its wound therapy and antimicrobial dressing products.
Traditionally, the physician has been the primary customer of the device company. However, as hospitals acquire physician practices and physicians seek employment at hospitals, most device companies would admit that they really don't know their customer's new boss.